Cargando…
Immunotherapy for the Treatment of Triple-Negative Breast Cancer
At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast ca...
Autores principales: | Tolaney, Sara M., Shaw, Lindsay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126339/ https://www.ncbi.nlm.nih.gov/pubmed/35663156 http://dx.doi.org/10.6004/jadpro.2022.13.3.23 |
Ejemplares similares
-
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022) -
Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments
por: Greene, Heather R., et al.
Publicado: (2020) -
Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021) -
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022) -
Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)